OBJECTIVE: Universal antenatal screening and intrapartum antibiotic prophylaxis are recommended to prevent perinatal Group B streptococcus (GBS) disease. Vancomycin use is recommended only for women at high risk for beta-lactam anaphylaxis with GBS cultures resistant to clindamycin and erythromycin. We sought to evaluate the use of vancomycin in GBS positive women undergoing vaginal delivery and describe trends over time. STUDY DESIGN: An administrative inpatient database that includes medications was analyzed to evaluate antibiotic use in women admitted for delivery from January 2006 to March 2015. Women were included if they had a vaginal delivery. Primary outcome was receipt of vancomycin by GBS status. Secondary outcomes included trends in vancomycin use, trends in antibiotic use overall among GBS positive women, and types of antibiotics used in this setting. RESULTS: Of 3,758,149 women admitted for vaginal delivery, 655,351 (17.4%) were coded as GBS positive. Of these, 13,215 (2.02%) received vancomycin during their hospitalization. Among GBS positive women the proportion who received vancomycin increased significantly from 0.76% to 3.14% over the study period; use of vancomycin also increased concurrently among GBS negative women from 0.15% to 0.37% (Figure 1) . Overall, 528,335 (80.4%) of GBS positive women received any antibiotic during their hospitalization and the proportion receiving antibiotics decreased significantly from 84.2% in 2006 to 76.0% in 2015. The most common antibiotics administered to GBS positive women undergoing vaginal delivery were penicillin, ampicillin, and erythromycin (Table 1) .
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CONCLUSION: Use of vancomycin among GBS positive women increased over the study period. This trend may be due to a combination of (i) increased penicillin allergies, (ii) increased antibiotic resistance, and (iii) less frequent testing of antibiotic sensitivities for penicillin-allergic patients. Hospital level systems improvements may be needed to increase obtainment of sensitivities for penicillinallergic women and reduce unnecessary use of this broad spectrum antibiotic.
625 Impact of excess weight gain on risk of postpartum infection in class III obesity OBJECTIVE: Obesity increases postpartum infectious morbidity. However, the impact of gestational weight gain on that risk remains unclear, especially in morbidly obese women. We aimed to assess the impact of gestational weight gain >20 pounds (lbs) (more than Institute of Medicine (IOM) recommendations) on postpartum infectious morbidity in morbidly obese women. 
